About Fate Therapeutics
Fate Therapeutics is a publicly listed company based in San Diego (United States) founded in 2007. Cellular immuno-therapeutics for cancer and immune disorders are developed. It operates on a HealthTech model. Fate Therapeutics has raised $78.19 million across 15 funding rounds from investors including Johnson & Johnson, Arch Venture Partners and Military Health. The company has 181 employees. Fate Therapeutics offers products and services including FT819, FT825, FT836, FT839, and FT522. Its focus areas include Biotechnology and Cell Therapy. Its legal entity is Fate Therapeutics, Inc. Its competitors include Moderna, C4 Therapeutics and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Fate Therapeutics is focused on the development of innovative cell therapies targeting autoimmune diseases and cancer. The company utilizes an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. These products are designed with novel synthetic controls to deliver multiple therapeutic mechanisms. Solutions are aimed at overcoming limitations in the manufacture, development, and commercialization of cell therapies. The company operates within the healthcare and biotechnology sectors, striving to make cell therapy delivery routine and accessible to patients globally.
- Headquarters San Diego, United States
- Employees 181
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website fatetherapeutics.com
- Social LinkedIn
- Legal Name Fate Therapeutics, Inc.
- Annual Revenue$6.65 M (USD)-51.24as on Dec 31, 2025
- Net Profit-$136.31 M (USD)26.82as on Dec 31, 2025
- EBITDA-$133.7 M (USD)24.28as on Dec 31, 2025
- Total Equity Funding$78.19M (USD)
in 15 rounds
- Latest Funding Round$50M (USD), Post-IPO
Jul 2020
- InvestorsJohnson & Johnson
& 8 more
- Employee Count181
Products & Services of Fate Therapeutics
Fate Therapeutics offers a comprehensive portfolio of products and services, including FT819, FT825, FT836, FT839, and FT522.
Cell therapy candidate for autoimmune diseases and cancer.
Cell therapy developed for treating serious medical conditions.
Cell therapy aimed at addressing life-threatening health issues.
Cell therapy designed for critical disease treatment applications.
Cell therapy focused on innovative treatment for diseases.
Funding Insights of Fate Therapeutics
Fate Therapeutics has successfully raised a total of $78.19M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.19M
- Total Rounds 15
- Last Round Post-IPO — $50M
- First Round $12.95M
(Nov 2007)
- Investors Count 9
Latest 10 of 15 funding rounds of Fate Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $50M | Post-IPO | – | – | – |
| Apr 2020 | $100M | Post-IPO | – | – | |
| Dec 2017 | $46M | Post-IPO | – | – | – |
| Dec 2016 | $56.75M | Post-IPO | – | – | – |
| Aug 2016 | $10.29M | Post-IPO | – | – | – |
| May 2015 | $8M | Post-IPO | – | – | – |
| May 2015 | $35M | Post-IPO | – | – | – |
| Aug 2013 | $20M | Series C | – | – | – |
| Aug 2012 | $9.24M | Series B | – | – | – |
| Apr 2011 | $2.1M | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Fate Therapeutics
Fate Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson, Arch Venture Partners and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| astellasventure.com | ||||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
| takedaventures.com | ||||
Early-stage VC investments are focused primarily on US companies. | ovpevents.com | Seattle, United States | ||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Healthcare solutions are provided by Johnson & Johnson globally. | 1886 | jnj.com | New Brunswick, United States | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Fate Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fate Therapeutics
78 people are tracked at Fate Therapeutics (26 in leadership, 9 in board & advisors, 43 in team); the tracked headcount is 181.
| Name | Role | Group |
|---|---|---|
Bob Valamehr | Chief Research & Development Officer | Leadership |
Kamal Adawi | Chief Financial Officer | Leadership |
Betsy Rezner | Senior Director, Product Characterization And Analytical Development | Leadership |
Claudette B. | Director, Clinical Science | Leadership |
Scott Wolchko | President & CEO | Leadership |
Cindy Tahl | Chief Legal And Compliance Officer | Leadership |
Michelle McNichols | Associate Director Quality Assurance Operations | Leadership |
Andrew Henry | Sr Vice President Clinical Operations | Leadership |
Julia Richter | Director, Microbiology | Leadership |
Jessica Francis | Vp, HR & Operations | Leadership |
Victor Hong | VP Finance | Leadership |
John Goulding | Director Of Research Development | Leadership |
Omotunde Babalola | Senior Vp, Technical Operations | Leadership |
Scott Breier | Associate Director, Facilities Operations & Engineering | Leadership |
Kate Duvall | Director, Corporate Controller | Leadership |
Martin Hosking | Director | Research And Development | Leadership |
Jon Rosen | Sr. Director, Research & Technology Core | Leadership |
Wei Zhao | Senior Director Of Data Science | Leadership |
Raedun Clarke | Executive Director, Technical Operations | Leadership |
Vaneet Sandhu | Vice President Clinical Development, Head Of Autoimmunity | Leadership |
58 more people are available in the full profile.
Complete people profiles for Fate Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Fate Therapeutics
Fate Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FATE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Oct 2013
- Listed onNASDAQ: FATE
- Listed entityFate Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS31189P1021
- Share price$2.00 (-6.1% on the day) · 2026-10-13
- Market capitalisation$239.6M
- EPS (diluted, trailing year)$-1.05
- Volume (last session)953,482
Financials of Fate Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $6.7M | -$136.3M | -$133.7M |
| 2024 | $13.6M | -$186.3M | -$176.6M |
| 2023 | $63.5M | -$160.9M | -$159.3M |
| 2022 | $96.3M | -$281.7M | -$294.6M |
| 2021 | $55.9M | -$212.2M | -$211.1M |
Detailed financial statements for Fate Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Fate Therapeutics
4 dated milestones of Fate Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Fate Therapeutics is founded.
- Funding First funding round of $13.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Fate Therapeutics
Fate Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, C4 Therapeutics and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Fate Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fate Therapeutics
The website of Fate Therapeutics (fatetherapeutics.com) receives about 9.3K visits a month and ranks #2,481,408 among all websites worldwide, #3,408 in Biotechnology and Pharmaceuticals.
- Monthly visits9.3K
▲ 15.3% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,481,408
among all websites
- Category rank#3,408
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.2
- Average visit43 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Fate Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharming.com | 100% | 16.8K | #1,623,426 | View details | |
mayoresearch.mayo.edu | mayoresearch.mayo.edu | 66% | – | ||
med.monash.edu.au | med.monash.edu.au | 66% | – | ||
pharmguse.net | pharmguse.net | 66% | – | ||
lupus.org | lupus.org | 59% | #234,476 | – |
Top companies in Cell Therapy
3 companies that operate in the same segment as Fate Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fate Therapeutics
Complete news archive for Fate Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fate Therapeutics
Fate Therapeutics was founded in 2007.
Fate Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Fate Therapeutics is a funded company, having raised a total of $78.19M across 15 funding rounds to date. The company's 1st funding round was a Grant of $2.1M, raised on Nov 2007.
Fate Therapeutics has 181 employees.
Annual revenue of Fate Therapeutics is $6.65M as on Dec 31, 2025.
Fate Therapeutics is focused on the development of innovative cell therapies targeting autoimmune diseases and cancer. The company utilizes an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. These products are designed with novel synthetic controls to deliver multiple therapeutic mechanisms. Solutions are aimed at overcoming limitations in the manufacture, development, and commercialization of cell therapies. The company operates within the healthcare and biotechnology sectors, striving to make cell therapy delivery routine and accessible to patients globally.
Fate Therapeutics's top competitors include Moderna, C4 Therapeutics and Forge Biologics.
Fate Therapeutics offers FT819, FT825, FT836, FT839, and FT522.
Yes, Fate Therapeutics is publicly traded on NASDAQ under the ticker symbol FATE.
Fate Therapeutics has 9 investors. Key investors include Johnson & Johnson, Arch Venture Partners, Military Health, Astellas Venture Management, and Polaris Partners.
Fate Therapeutics operates through Fate Therapeutics, Inc..